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Abstract
Background: Neuroinflammation (NI) is a key feature in the pathogenesis and progression of infectious and
non-infectious neuropathologies, and its amelioration usually improves the patient outcome. Peripheral
inflammation may promote NI through microglia and astrocytes activation, an increased expression of
inflammatory mediators and vascular permeability that may lead to neurodegeneration. Several anti-
inflammatory strategies have been proposed
to control peripheral inflammation. Among them, electrical stimulation of the vagus nerve (VNS) recently
emerged as an alternative to effectively attenuate peripheral inflammation in a variety of pathological
conditions with few side effects.
Considering that NI underlies several neurologic pathologies we explored herein the possibility that electrically
VNS can also exert anti-inflammatory effects in the brain.
Methods: NI was experimentally induced by intraperitoneal injection of bacterial lipopolysaccharide (LPS) in
C57BL/6 male mice; VNS with constant voltage (5 Hz, 0.75 mA, 2 ms) was applied for 30 s, 48 or 72 h after
lipopolysaccharide injection. Twenty four hours later, pro-inflammatory cytokines (IL-1β, IL-6, TNFα) levels were
measured by ELISA in brain and spleen extracts and total brain cells were isolated and microglia and
macrophage proliferation and activation was assessed by flow cytometry. The level of ionized calcium binding
adaptor molecule (Iba-1) and glial fibrillary acidic protein (GFAP) were estimated in whole brain extracts and in
histologic slides by Western blot and immunohistochemistry, respectively.
Results: VNS significantly reduced the central levels of pro-inflammatory cytokines and the percentage of
microglia (CD11b/CD45low) and macrophages (CD11b/CD45high), 24 h after the electrical stimulus in LPS
stimulated mice. A significantly reduced level of Iba-1 expression was also observed in whole brain extracts and
in the hippocampus, suggesting a reduction in activated microglia.
Conclusions: VNS is a feasible therapeutic tool to attenuate the NI reaction. Considering that NI accompanies
different neuropathologies VNS is a relevant alternative to modulate NI, of particular interest for chronic
neurological diseases.
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Background
It is widely accepted that inflammation is beneficial
for the organism by limiting the infectious process and
promoting tissue repair and recovery. However, inappro-
priate inflammation (in time, place, and/or magnitude) is
increasingly implicated in a wide range of pathologies [1].
This dual role of inflammation is also observed in the
central nervous system (CNS), where neuroinflammation
(NI) may take part in disease resolution [2] but also cause
severe damage [3]. NI occurs when microglia, astrocytes
(brain-resident cells), and perivascular macrophages at the
blood-brain barrier (BBB) are activated. These cells
produce and release pro- inflammatory mediators that in
turn may recruit components of the adaptive immunity
[4]. Altogether, these events may result in myelin and
neuron damage with ensuing neuronal dysfunction [3].
It has been shown that the CNS senses peripheral
inflammation through different pathways, resulting in
central inflammation and in a “sickness behavior” profile
that may include depression, anxiety, anorexia, and/or
lethargy [5]. This communication could proceed through
circumventricular organs [6] as well as by the proper
lymphatic system, considering the findings recently
published [7]. It is also feasible that cytokines can be
transported from the periphery to the CNS across the
BBB [8], which may become more efficient if some
degree of disruption of this barrier occurs [9].
Systemic injection of bacterial lipopolysaccharide
(LPS) into mice has been widely used to induce central
inflammation experimentally [10, 11]. A single systemic
administration of LPS (5 mg/kg, i.p.), resulted in a rapid
activation of brain microglia and an increased expression
of brain pro-inflammatory factors, such as TNFα and
IL-1β, that remained elevated for 10 months, while
peripheral TNFα (serum and liver) declined after 9 h
and 1 week in serum and liver, respectively [11].
Multiple mechanisms, including the vagus nerve
circuit, have evolved to promote a balanced status
between local and systemic inflammation, thus preven-
ting immunopathologies [12]. Through efferent and
afferent fibers, the vagus nerve regulates numerous
central and peripheral key processes [13]. The ascending
afferent vagal nerve fibers can inform the CNS of the
presence of peripheral inflammation [14]. It has been
proposed that vagal efferent fibers release acetylcholine
(Ach), which can interact with α7-subunit-containing
nicotinic receptors in tissue macrophages and other
immune cells to rapidly inhibit the synthesis/release of
pro-inflammatory cytokines such as TNFα, IL-1β, IL-6,
and IL- 18 [15–18]. However, the direct role of efferent
cholinergic vagal nerve fibers in blunting inflammation
has been questioned [19–21] since experimental evidence
suggests that electric vagus nerve stimulation (VNS)
inhibits inflammation indirectly [20] by eliciting a
sympathetic response that can mediate anti- inflam-
matory and other immunoregulatory effects [22–24].
Independently of the mechanisms underlying the
anti-inflammatory properties of VNS, its effect has
been extensively confirmed under experimental conditions
in inflammatory pathologies like arthritis, stroke, cardio-
vascular diseases, and lupus [25–27]. These findings,
together with the use of VNS in humans to treat refrac-
tory partial-onset seizures and severe recurrent refractory
depression, give rise to great expectations on its use
to ameliorate chronic NI and to contribute to the control
of the progression of neurodegenerative diseases [28–30].
Herein, the effectiveness of VNS to control the NI




C57BL/6 J mice were originally purchased from Jackson
laboratories, USA, and further bred in a pathogen-free
facility at our Institute. Seven to eight week-old male
mice were divided into four groups for LPS kinetics
experiments and into five groups to test the effect of
VNS. Mice were kept in Plexiglas boxes before the
experiments. Food and water were allowed ad libitum.
After surgery, all mice were housed individually at 22 ±
3 °C with a 12 h light-dark cycle. Experiments were
repeated two to four times each.
Surgery and Electric Vagus Nerve Stimulation (VNS)
To perform its implantation, an incision was performed in
the ventral side of the neck of mice to isolate the left
cervical vagus nerve, and a platinum electrode was placed
under the exposed nerve (Fig. 1a). The view of the
implanted electrodes by CTscan is illustrated in Fig. 1b.
All mice were anesthetized with ketamine (90–
100 mg/kg) and xylazine (10 mg/per kg). Bipolar electrodes
were placed on the cervical vagus nerve trunk and
connected to a stimulation module (designed by the
Centro de Ciencias Aplicadas y Desarrollo Tecnológico,
CCADET, UNAM, Mexico). After electrodes implan-
tation, mice were randomly divided in five different
groups that received: group 1, (sham, non-LPS treated
and with no electric stimulus); group 2, only treated
with isotonic saline solution (ISS); group 3, only VNS
treated; group 4, only treated with LPS and group 5,
LPS and VNS treated. The parameters for VNS were
calculated based on previously reported data [31].
VNS stimulated anesthetized mice received a constant
voltage of 5 Hz, 0.75 mA, for 30 s.
LPS-induced inflammation
A model of CNS inflammation induced by systemic LPS
administration was used, as previously described [11].
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Mice received either 5 mg/kg of LPS from Escherichia
coli serotype 0111:B4 (Sigma, St. Louis, MO) injected
intraperitoneally (i.p.) or an equivalent volume of saline
solution vehicle (ISS), 0.9 % NaCl (endotoxin-free
isotonic saline solution) (PiSA, Mexico) as a control. To
determine the best point time that LPS induces inflam-
mation, the peripheral and central inflammatory response
was assessed before and 2, 3, and 4 days after LPS
administration (Fig. 2a).
Central and Peripheral Inflammatory mediators
Mice were anesthetized as described above, and subman-
dibular bleeding was performed before and at different
times after LPS treatment (Fig. 2a). LPS- treated mice
were employed to evaluate the VNS as an anti-
neuroinflammatory treatment (Fig. 2b). All mice were
perfused by cardiac puncture with 250 mL of sterile
NaCl 0.15 M to prevent the presence of peripheral
molecules in central tissues. Brains were rapidly removed
and half of them were processed for protein extrac-
tion to quantify the levels of TNFα, IL-1β, and IL-6
and for western blot analysis. The other half of the
brains were fixed for immunofluorescence analysis as
described below. Only for the LPS kinetic experiment
(Fig. 2a), spleens were removed to estimate the level
of peripheral inflammatory soluble mediator because
they offer more material than the insufficient amount
of sera of each mouse to measure these mediators.
Protein extraction
Snap-frozen brain hemispheres and spleens were
homogenized in a lysis buffer (50 mM HEPES, 150 mM
NaCl, 1 % Nonidet-p40, 0.5 % sodium deoxycholate,
0.1 % SDS) containing complete protease inhibitors
(Roche, IN). Samples were then centrifuged at 16,000 × g
for 15 min at 4 °C and supernatants were collected for
analysis. The total amount of proteins in the soluble
extract was measured using the Lowry method [32].
Cytokine Enzyme-Linked Immunosorbent Assay (ELISA)
Commercial kits were used to quantify the concentration
of the pro-inflammatory cytokines IL-1β, IL-6, and TNFα
in brain and spleen extracts (BioLegend, San Diego, CA).
Briefly, sandwich ELISAs were performed in 96-well,
flat-bottom MaxiSorp microtiter plates (Nunc, Roskilde,
Denmark). Microplates were coated with the capture anti-
body for 18 h at 4 °C. After washing with PBS-Tween-20
(0.05 %) and blocking for 60 min at room temperature
with 2 % PBS-BSA, plates were incubated at room
temperature for 2 h with standard or samples, washed
three times, and incubated for 1 h with the detection
antibody at room temperature.
Fig. 1 Procedure of implanted electrodes and location by CTscan. a Procedure of electrode insertion into the vagus nerve. 1. Photograph showing the
trachea and the sternocleidomastoid muscle, carotid. 2. Sheath with carotid and vagus nerve. 3. Vagus nerve is shown isolated. 4. Electrodes applied to
the vagus nerve. t = trachea, ECOM= sternocleidomastoid, c = carotid, VN = vagus nerve. b Representative view of the electrodes inserted in the vagus
nerve by Computed Tomography Scan
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Bound detection antibodies were identified using
1:1000 diluted Avidin-HRP and TMB as a substrate.
Optical density was read before and after the reaction
was stopped with H2SO4 2 N at 450 and 630 nm,
respectively. Results were expressed in pg/mL per mg of
protein in the respective soluble extract.
Western blot
Proteins were separated by electrophoresis on 12 %
Tris-glycine polyacrylamide gel at 150 V for 1 h 30 min,
(for Iba-1 detection) and on 4–12 % polyacrylamide
precast NuPAGE Bis-Tris gel (Invitrogen) at 200 V for 2 h
30 min (for GFAP detection), and transferred onto a
PVDF membrane (Bio-Rad, Hercules, CA) using a
semi-dry blot system (Bio-Rad) at 25 V for 50 min.
Membranes were blocked in PBS/2 % fat-free dry milk
overnight at 4 °C and then incubated with primary
antibodies (rabbit anti-β- actin and rabbit anti-GFAP
[1:1000] or rabbit anti-Iba-1 [1:2000]) diluted in PBS/
milk/0.2 % Triton X-100 overnight at 4 °C. After washing
with PBS/0.2 % Tween, membranes were incubated
with HRP-conjugated anti-rabbit IgG (Invitrogen) for
2 h at room temperature. Immunoreactive bands were
detected by chemiluminescence using the Super Signal
West Dura Extended Duration Substrate kit (Pierce, IL).
The NIH ImageJ software was used for densitometric
analysis of bands. β-actin served as an internal control.
Immunofluorescence Analysis (IFC)
The half of each brain obtained as described above
was fixed in 4 % buffered formalin at 4 °C overnight.
Free-floating 30 μm-thick mouse brain sections were
processed as previously described [33]. After antigen
retrieval by incubating in citrate buffer (0.01 M citric
acid, 0.05 % Tween 20, pH 6.0) at 70 °C for 50 min,
samples were thoroughly washed several times with
TBS and blocked with a solution of 2 % IgG-free
albumin (Sigma) in TBS for 20 min at room temperature.
Brain sections were then incubated overnight at 4 °C
with rabbit anti-GFAP (Invitrogen) or anti-Iba-1 (WAKO,
VA) polyclonal antibody in TBS-2 % BSA to detect
astrocytes or microglia, respectively. After washing,
sections were incubated for 1 h at room temperature
with AlexaFluor 594 goat anti-rabbit IgG (Molecular
Probes, OR) diluted in TBS-2 % BSA. Samples were
mounted onto glass slides in Vectashield medium
(Vector Laboratories, CA) containing DAPI for nuclei
imaging. Samples were viewed on an Olympus Ix51
microscope equipped with a DP71 camera (Nikon Instru-
ments Inc., NY).
Brain cells Isolation
Parallel experiments in other groups of mice were
performed for Flow cytometry analysis. Mice were anes-
thetized with a mixture of ketamine and xylazine, as de-
scribed above. Brain cells isolation was obtained following
a method previously reported, with minor modifications
[34, 35]. Briefly, mice were perfused by cardiac puncture
with 250 mL of sterile GKN approximately (8 g/L NaCl,
0.4 g/L KCl, 3.56 g/L Na2HPO4∙12H2O, 0.78 g/L
NaH2PO4∙2H2O, 2 g/L D-(+)-glucose, pH 7.4) to remove
all peripheral cells of the central tissues. Brains were
recovered in ice-cold GKN containing 0.02 % (w/v) iso-
tonic bovine seroalbumin (GKN-BSA), and mechanically
Fig. 2 Experimental design line. a LPS or ISS were injected at day 0. The inflammatory peripheral and central status was evaluated before and at
the different times after injection. b Electrodes were implanted at day 0. Five days later, mice were randomly divided into five groups: sham,
isotonic saline solution treated mice (ISS), Vagus Nerve Stimulation (VNS), LPS and LPS + VNS
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dissociated using a 100-μm mesh. The sediment was
collected in a 50-mL centrifuge tube, washed with
GKN-BSA, and centrifuged at 400 × g for 10 min at
slow brake. The pellet was treated with 5 mL digestion
buffer (4 g/L MgCl2, 2.55 g/L CaCl2, 3.73 g/L KCI,
and 8.95 g/L NaCl, pH 6.7) supplemented with 15 U
of type-II collagenase and 500 U of DNase I per brain
for 1 h at 37 °C, washed with GKN-BSA, and centri-
fuged at 400 × g for 10 min at slow brake.
The pellet obtained was resuspended in 4 mL 30 %
Percoll with GKN-BSA and placed on a gradient of 70 %
and 37 % of Percoll, centrifuged at 500 × g for 20 min
and resuspended in PBS (1X-0.02 % NaN3). Cells were
counted, stained with specific antibodies and analyzed
by flow cytometry.
Flow cytometry
Isolated brain cells were treated with CD16/32 antibody
to block Fc receptors and stained for surface markers as
previously reported [35]. Cells were labeled with anti
CD11b-FITC and anti-CD45-APC or isotype-matched
control antibodies (BioLegend) and analyzed using a
FACSCalibur flow cytometer and the Cell-Quest Pro
software. For analysis, two cell populations were distin-
guished using antibodies against CD11b and CD45.
As both microglia cells and macrophages are CD11b
positive, the difference in the level of CD45 expres-
sion was used to distinguish between microglia, which
expresses low CD45 levels, and macrophages, that
express high CD45 levels [36]. Microglia and macro-
phage activation status was assessed by examining
the increase in medium fluorescence intensity for
CD11b + in CD11b+/CD45low and CD11b+/CD45high
cell population [37].
Statistical analysis
All analyses were carried out using Instat Statistical
software (GraphPad Software Inc., La Jolla, CA, USA).
Data are reported as mean ± standard error (SEM).
Differences between groups were evaluated using the
Kruskal-Wallis test (non- parametric ANOVA test) or
one-way Analysis of Variance plus the Tukey-Kramer
multiple comparisons test, considering the distribution
of the data, as described in each Table and Figure.
Results
Effect of LPS on Peripheral and Central Pro-Inflammatory
Cytokine Levels
To identify the number of days after LPS treatment in
which levels of NI parameters were adequate to evaluate
the anti-NI effects of VNS, peripheral and central levels
of pro-inflammatory cytokines (IL-6, IL-1β, and TNFα)
were analyzed after LPS administration. As show in
Table 1, a statistically significant increase in central
TNFα levels was observed 4 days after LPS injection.
IL-6 was found elevated 1 and 4 days after LPS injection.
IL-1β was increased from the second day after LPS injec-
tion and remained elevated until day four. As expected,
no significant differences in the levels of peripheral cyto-
kines were found after LPS treatment at these time points
(data not shown).
Effect of LPS on Brain Microglia and Macrophages
To evaluate the central cellular inflammatory effects of
systemic LPS injection, the percentage of CD11b
+/CD45low (microglia) and CD11b+/CD45high (macro-
phages) were estimated daily for 3 days after LPS injec-
tion starting at day 2. As shown in Fig. 3, the relative
percentage of microglial cells and macrophages was
increased from day 2 to day 3 after LPS treatment lowe-
ring by day 4. Activation of the microglia e.g. increased
in the mean intensity fluorescence of CD11b was found
at day two and three whilst activation of macrophages
was observed only at day two after LPS injection.
Effect of VNS on the Central Expression of Cytokines
After electrodes were placed on the cervical vagus as
described in Materials and Methods (Fig. 1), mice were
randomized into five groups: sham and four experimen-
tal groups, treated with ISS or LPS or VNS or LPS +
VNS (electrode stimulation was applied only for those
described as VNS).
Since the concentration of IL-6, IL-1β, and TNFα
showed significant changes on day four after LPS injec-
tion only at central levels, these cytokines were measured
in the brain extracts 1 day after VNS (Fig. 2b). As shown
in Table 2, increased central levels of the three cytokines
were detected in LPS-treated mice. Twenty- four hours
after VNS, a statistically significant decrease in the level
of the three cytokines was observed compared to the
Table 1 Cytokine levels (pg/mg of protein) in brain extracts
from ISS- or LPS-treated mice
TNFα IL-1β IL-6
ISS 0.24 ± 0.04a 4.9 ± 1.1a 0.2 ± 0.6a
Days after LPS treatment:
2 0b 31.5 ± 4.3a 1.9 ± 1.4a
3 0b 18.8 ± 3.3a,b 0.2 ± 0.2a
† 4 3.5 ± 0.4a,c 112 ± 19.2c 46.2 ± 4.6b
Mean ± SEM of brain cytokine levels in saline- or LPS-treated C57BL/6 J male
mice (n = 5, † one mouse dead after LPS injection). Different literals a,b,c
indicate significant differences in the level of each cytokine between
saline-treated and 2, 3, and 4 days post-LPS treated mice using the
Kruskal-Wallis test (non-parametric ANOVA), TNFα (p = 0.0004), IL-1β
(p = 0.0003), IL-6 (p = 0.008). Data are from one out of three experiments
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LPS-treated group. No effect on the level of the three
cytokines was observed in sham or VNS-treated mice.
Effect of VNS on CD11b/CD45low and CD11b/CD45high
Brain Cells
Considering the results obtained in the kinetic study
(Fig. 3), 2 days after ISS or LPS treatment, the vagus of
the mice were electrically stimulated and the effect on
microglial cells and macrophages was evaluated 24 h
later (Fig. 2b). LPS significantly increased the percentage
of CD11b+/CD45low and CD11b+/CD45highcells.
Electric stimulation of the vagus nerve did not signifi-
cantly affect the percentage of CD11b+/CD45low cells
as compared to that of non-treated or saline-injected
animals.
The percentage of CD11b+/CD45high cells also decreased
after VNS treatment but in a lower extent (Fig. 4b). The
mean intensity of fluorescence of CD11b in CD11b
+/CD45low and CD11b+/CD45high windows, was also found
Fig. 3 a A representative dot plot of isolated brain cells from saline or LPS treated mice analyzed by flow cytometry. b Mean ± SD of the percentage
of CD11b/CD45low and CD11b/CD45high before and 48, 72, and 96 h after LPS treatment and mean ± SD of the fluorescence intensities of CD11b (c).
Different literals indicate significant differences between the different groups (p < 0.05) using the Kruskal-Wallis test (non-parametric ANOVA) plus the
Dunn’s multiple comparisons test. Data are representative of four experiments
Table 2 Cytokine (pg/mg of protein) levels in brain extracts of
sham and treated mice
TNFα IL-1β IL-6
Sham 0.94 ± 0.25a 10.54 ± 3.7a 0.78 ± 0.20a
ISS 0.34 ± 0.3a 4.1 ± 0.7a 0.62 ± 0.03a
VNS 0.06 ± 0.06a 7.4 ± 3.8a 0.28 ± 0.06a
††LPS 3.7 ± 0.38b 184 ± 1.87b 22.3 ± 0.72b
†LPS + VNS 1.47 ± 0.04a 20.4 ± 1.55a 1.19 ± 0.08a
Mean ± SEM of brain cytokine levels in groups of five C57BL/6 male mice each
(† one and †† two mice dead after LPS injection). VNS and LPS + VNS reported
levels of central cytokines 24 h after VNS treatment in mice injected or not
with LPS 3 days before (Fig. 2b). Different literals indicate significant
differences in each cytokine level between the different treatments using the
Kruskal-Wallis test (non- parametric ANOVA), TNFα (P = 0.025), IL-1β (P = 0.004),
IL-6 (P = 0.005). Data are from one out of four experiments
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significantly increased in LPS-treated mice and was reduced
in a statistically significant manner by VNS (Fig. 4c).
Effect of VNS on Iba-1 and GFAP Expression
To further characterize the effect of peripheral LPS
administration and VNS on microglial activation, a
Western blot assay using brain homogenates was
performed. Increased levels of Iba-1, a microglia marker,
were found in LPS- treated mice with respect to
ISS-treated. Importantly, VNS significantly reduced the
expression of Iba-1 (Fig. 5a and b). To characterize even-
tual morphological changes in microglia, the expression of
Iba-1 was evaluated by immunohistochemistry. Four days
after LPS treatment, microglial cells with retracted pro-
cesses and enlarged cell bodies, some with curved contour,
were observed after staining with anti-Iba-1 antibody
(Fig. 5c). Iba-1 expression was significantly increased in
animals of the LPS compared to mice from ISS, VNS
and LPS + VNS groups (Fig. 5c).
As shown in Fig. 6, no significant differences in
GFAP expression in astrocytes were observed among
experimental groups (as determined by Western blot
and immunohistochemistry using an anti-GFAP anti-
body). These results are in agreement with previous
reports [38].
Discussion
VNS has been found efficacious in controlling LPS-
induced acute peripheral inflammation [15]. VNS also
attenuates the chronic systemic inflammation that ac-
companied different experimental inflammatory diseases
such as mouse arthritis [39], rat heatstroke [40], and
rat pulmonary inflammation [41] through vagal anti-
inflammatory pathway. There is also evidence that
VNS also limits the central influx of activated T cells
in the lesioned facial motor nucleus [42] and also reduces
the central inflammatory response in the murine expe-
rimental autoimmune encephalomyelitis [43]. It was
recently reported that VNS also control the disease seve-
rity and inflammation in severe human rheumatoid
arthritis [44].
Fig. 4 a Representative dot plot of isolated brain cells analyzed by flow citometry. b Mean ± SD of the percentage of CD11b/CD45low and
CD11b/CD45high cells and the respective Mean ± SD of the fluorescence intensities of CD11b (c) of five mice per group. Data are representative
of two different independent assays. Different literals indicate significant differences in the percent of CD11b/CD45low and CD11b/CD45high cells
(P < 0.05) between the different groups using the Kruskal- Wallis test (non-parametric ANOVA) plus the Dunn’s multiple comparisons test
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In this study, clear evidence of the anti-neuroinflammatory
effect of the VNS is shown. While the anti-inflammatory
effect of VNS exerted via α7-nicotine cholinergic receptor
stimulation, is well established our studies showed for
the first time that this procedure inhibits IN.
The increased central levels of pro-inflammatory
cytokines induced by peripheral LPS injection were
significantly reduced after VNS treatment. The percent
of microglia (CD11b+/CD45low) was also significantly
reduced after VNS in LPS-treated mice (Fig. 4b). In
agreement with these findings, a reduction in the levels
of Iba-1, a calcium-binding protein specifically expressed
in microglia/macrophages, was also observed [38].
Considering that microglia proliferation is part of the
activation process, it is feasible that activation occurred
earlier after LPS treatment [45, 46]. It is also interesting
to note that VNS significantly decreases the percentage
and the activation of central macrophages CD11b
+/CD45high (Fig. 4).
As shown in Fig. 5, a decrease in Iba-1 expressionwas dem-
onstrated by Western blot and by immunohistochemistry in
the hippocampus of VNS-treated mice, a finding that
supports the effective control of microgliosis by this
treatment. This effect on key resident immune cells of the
CNS is critical in controlling the neuroinflammatory
response. Microglia activation has a significant effect
on NI progression, since glial cells are the primary
source of pro-inflammatory cytokines in the brain. In
addition, recent evidence point to the significant con-
tribution of microglial proliferation in the progression
of a chronic neurodegeneration induced in a murine
model of prion disease [47]. Interestingly in the latter
study low levels of inflammatory cytokines were detected,
suggesting that microglial proliferation is implicated in
the progression of the disease without direct partici-
pation of inflammatory cytokines. On the other hand,
in our study astrocytes were not activated 4 days after
LPS administration, irrespective of whether mice were
given VNS or not. Our results are in agreement with
previous reports where authors did not observe diffe-
rences in GFAP immunoreactivity at any time point after
one or four repeated peripheral LPS challenge [38]. The
Fig. 5 Analysis of brain Iba-1 expression in ISS, VNS, LPS, and LPS + VNS- treated mice. a Representative Western blot showing Iba-1 and β-actin.
b Western blot analysis of Iba-1 in whole brain homogenates of SSI, VNS, LPS, and LPS + VNS-treated mice. Each column represents the level of
Iba-1 expressed as mean ± SEM, normalized to β-actin in a same gel. Different literals indicate significant differences in the expression level of
Iba-1 among the different groups using one-way Analysis of Variance plus the Tukey-Kramer multiple comparisons test. F (3,16) = 6.7, p < 0.004.
c Representative mouse brain sections of the different groups stained with anti-Iba-1 antibody (to detect microglia). Bottom images represent a
nine-fold magnification of the region outlined in the box in the corresponding upper image. In LPS-treated mice, higher numbers of microglia
with morphological characteristics of activated cells were observed
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western blot assays for evaluation of Iba-1 and GFAP
levels (Figs. 5 and 6) were performed using whole brain
homogenates. Considering that the GFAP glial protein is
heterogeneously expressed in astrocytes from different
brain regions and is extremely low in the cortex [48], its
expression in the hippocampus was analyzed and no
differences were observed between experimental groups
(data not-show).
Another point that merits comments is the low
frequency stimulation protocol used in this study for
VNS that favors the activation of the efferent rather than
afferent fibers of the VN [49].
Altogether, the findings reported here, let us to
propose VNS as a novel and useful alternative to modu-
late NI. This could be especially relevant since treating
NI remains an unsolved challenge. NI is a hallmark of
several infectious and neurodegenerative diseases [50–53],
and its control could result in a clear improvement of
the patients [54]. However, the available anti-inflammatory
tools are not appropriate for chronic treatments. Glu-
cocorticoids (GCs), particularly synthetic GCs like
dexamethasone and prednisone, are the drugs of choice
to treat NI. While both are highly effective immunosup-
pressive drugs to reduce NI, long-term treatment is
limited by side effects due to the high systemic doses
required to reach effective concentrations in the CNS
[55]. In contrast, VNS could be a much safer alternative
for chronic NI control. VNS has been applied for drug-
resistant epilepsy for 17 years with a good safety record
[56]. Moreover, it was approved for this indication by the
US Food and Drug Administration in 1997 and in 2001
in Europe and Canada. Since then, its use in neuromo-
dulation for epilepsy control has spread. Over 100,000
patients have been implanted until December 2012 with a
VNS device (“Cyberonics announces 100,000th patient
implant of VNS therapy”, ir.cyberonics.com/release
detail.cfm?ReleaseID = 728198) [57]. Its usefulness has
also been explored to treat neurodegenerative diseases
with some success [58].
Finally, it is worthy to mention that the wide accep-
tance of this new procedure to control chronic NI will
require further investigation to support its usefulness in
Fig. 6 Analysis of GFAP expression in the brain of ISS, VNS, LPS-treated and LPS + VNS-treated. a Representative Western blots showing GFAP and
β-actin levels. b Western blot analysis of GFAP in whole brain homogenates of untreated, VNS, LPS-treated, and LPS + VNS-treated mice. Each
column in the graph represents the level of GFAP expressed as Mean ± SEM, normalized to β-actin in a same gel. No significant differences
between GFAP levels were observed using one-way Analysis of Variance plus the Tukey-Kramer multiple comparisons test. F (3,16) = 0.44,
p = 0.72. c Representative mouse brain sections of the different groups of mice stained with anti-GFAP antibody (to detect astrocytes).
Bottom images represent a nine-fold magnification of the region outlined in the box in the corresponding upper image
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different pathological conditions. Considering the minor
undesirable side effects of this intervention, some work
aiming at reducing the cost of the electronic device
would be relevant, since it would offer a good thera-
peutic choice in non-developed countries.
Conclusions
In conclusion, this study provides clear evidence that
electric stimulation of the vagus nerve attenuates the
inflammatory response in the CNS induced by peri-
pheral LPS challenge. To our knowledge, this is the first
study in which the usefulness of VNS to control the NI
is reported. Albeit the mechanism that underlie the
anti-neuroinflammatory effects induced by VNS remains
to be elucidated, results shown herein open a new
therapeutic alternative of special interest to reduce
the NI involved in the evolution of several chronic
neuropathologies.
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